The microbiome as a source of new enterprises and job creation: Considering clinical faecal and synthetic microbiome transplants and therapeutic regulation

Lelie, Daniël van der; Taghavi, Safiyh; Henry, Christopher S.; Gilbert, Jack A.

doi:10.1111/1751-7915.12597

Cited by 9 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noted that the latter at no point can have negative nutritional attributes, such as raising allergic reactions. On the contrary, they may have certain special properties, such as being rich in high value amino acids or being capable of inducing a stimulation of the immuno-system …”

Section: Opportunities and Challengesmentioning

confidence: 99%

Microbes and the Next Nitrogen Revolution

Pikaar

Matassa

Rabaey

et al. 2017

Environ. Sci. Technol.

View full text Add to dashboard Cite

The Haber Bosch process is among the greatest inventions of the 20th century. It provided agriculture with reactive nitrogen and ultimately mankind with nourishment for a population of 7 billion people. However, the present agricultural practice of growing crops for animal production and human food constitutes a major threat to the sustainability of the planet in terms of reactive nitrogen pollution. In view of the shortage of directly feasible and cost-effective measures to avoid these planetary nitrogen burdens and the necessity to remediate this problem, we foresee the absolute need for and expect a revolution in the use of microbes as a source of protein. Bypassing land-based agriculture through direct use of Haber Bosch produced nitrogen for reactor-based production of microbial protein can be an inspiring concept for the production of high quality animal feed and even straightforward supply of proteinaceous products for human food, without significant nitrogen losses to the environment and without the need for genetic engineering to safeguard feed and food supply for the generations to come.

show abstract

Section: Opportunities and Challengesmentioning

confidence: 99%

Microbes and the Next Nitrogen Revolution

Pikaar

Matassa

Rabaey

et al. 2017

Environ. Sci. Technol.

View full text Add to dashboard Cite

show abstract

“…These therapeutic approaches are intended to treat CDI, and that can be used as an alternative for FMT. Synthetic microbial communities designed for transplants are expected to meet production, mode of action and safety standards ( Orenstein et al, 2015 ; van der Lelie et al, 2017 ). For instance, Seres health developed SER-109, a novel biological agent proposed to restore the balance in the gut microbiome, promoting resistance to pathogenic invaders like C. difficile ( Khanna et al, 2016 ).…”

Section: Industrial Applications and Interestsmentioning

confidence: 99%

“…Moreover, other formulations including strains belonging to Clostridia classes IV and XIVa were designed to modulate the immune response ( Atarashi et al, 2013 ). The original community of 17 strains (VE202) was developed by Vendanta Biosciences and Johnson and Johnson, and has provided an effective treatment for autoimmune disorders ( Reardon, 2014 ; Ratner, 2015 ; van der Lelie et al, 2017 ).…”

Section: Industrial Applications and Interestsmentioning

confidence: 99%

Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications

2017

View full text Add to dashboard Cite

The link between gut microbiota and human health is well-recognized and described. This ultimate impact on the host has contributed to explain the mutual dependence between humans and their gut bacteria. Gut microbiota can be manipulated through passive or active strategies. The former includes diet, lifestyle, and environment, while the latter comprise antibiotics, pre- and probiotics. Historically, conventional probiotic strategies included a phylogenetically limited diversity of bacteria and some yeast strains. However, biotherapeutic strategies evolved in the last years with the advent of fecal microbiota transplant (FMT), successfully applied for treating CDI, IBD, and other diseases. Despite the positive outcomes, long-term effects resulting from the uncharacterized nature of FMT are not sufficiently studied. Thus, developing strategies to simulate the FMT, using characterized gut colonizers with identified phylogenetic diversity, may be a promising alternative. As the definition of probiotics states that the microorganism should have beneficial effects on the host, several bacterial species with proven efficacy have been considered next generation probiotics. Non-conventional candidate strains include Akkermansia muciniphila, Faecalibacterium prausnitzii, Bacteroides fragilis, and members of the Clostridia clusters IV, XIVa, and XVIII. However, viable intestinal delivery is one of the current challenges, due to their stringent survival conditions. In this review, we will cover current perspectives on the development and assessment of next generation probiotics and the approaches that industry and stakeholders must consider for a successful outcome.

show abstract

“…El proceso de disbiosis está relacionado con diferentes tipos de enfermedades en el hospedero como infecciones crónicas, asma, alergia, rinitis, eccema, enfermedad infl amatoria intestinal, síndrome del colon irritable, enfermedad de Crohn, infecciones intestinales crónicas y diferentes formas de alergias a diferentes sustancias y alimentos. 44 El uso excesivo de antibióticos para el tratamiento contra las infecciones gastrointestinales puede afectar la composición normal de la microbiota y permitir un aumento en la proporción de las bacterias resistentes como Clostridium diffi cile, generando un proceso infl amatorio en el intestino. 45 La infección intestinal por cepas de Clostridium diffi cile resistentes a múltiples fármacos ha tenido resultados poco favorables con el tratamiento por antibióticos.…”

Section: Composición De La Microbiota En El Cuerpo Humanounclassified

La asociación de la microbiota humana con la inmunoglobulina A y su participación en la respuesta inmunológica

Sánchez‐Salguero¹,

Santos-Argumedo²

2018

RAM

View full text Add to dashboard Cite

Human microbiota is the aggregate of microorganisms that reside in our body. Its phylogenetic composition is related to the risk for suffering from inflammatory diseases and allergic conditions. Humans interact with a large number and variety of these microorganisms via the skin and mucous membranes. An immune protection mechanism is the production of secretory IgA (SIgA), which recognizes resident pathogenic microorganisms and prevents their interaction with host epithelial cells by means of immune exclusion. Formerly, it was thought that SIgA only function in mucous membranes was to recognize and exclude pathogens, but thanks to the use of massive sequencing techniques for human microbiota phylogenetic characterization, now we know that it can be associated with pathogenic and non-pathogenic microorganisms, an association that is important for functions the microbiota carries out in epithelia, such as regulating the capability of certain microbial species to settle on the skin and mucous membranes, and stimulation and regulation of the immune response and of the risk for the development of inflammatory problems, allergic conditions, autoimmune diseases, and even cancer. Established microbiota determines the type of bacterial species (and probably viral and protozoan species) that reside on the skin and mucous membranes, promoting microbial diversity.

show abstract

The microbiome as a source of new enterprises and job creation: Considering clinical faecal and synthetic microbiome transplants and therapeutic regulation

Cited by 9 publications

References 6 publications

Microbes and the Next Nitrogen Revolution

Microbes and the Next Nitrogen Revolution

Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications

La asociación de la microbiota humana con la inmunoglobulina A y su participación en la respuesta inmunológica

Contact Info

Product

Resources

About